Assessing Recursion Pharmaceuticals (RXRX) After A 58% One-Year Share Price Decline

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...